ARWR
ARROWHEAD PHARMACEUTICALS, INC.Marquee-fund ownership over time
This quarter's activity
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $23 | $74 | +226% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $23 | $74 | +226% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $23 | $74 | +226% |
| Renaissance Technologies re-entered | Q4 2024(8Q snapshot) | 6Q | $22 | $74 | +242% |
| AQR Capital Management | Q2 2025(8Q snapshot) | 4Q | $15 | $74 | +382% |
| D.E. Shaw | Q4 2025(8Q snapshot) | 2Q | $41 | $74 | +79% |
| Bridgewater Associates | Q1 2026 | 1Q | $64 | $74 | +16% |
| Point72 Asset Management | Q2 2026(8Q snapshot) | 1Q | $0.00 | $74 | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at ARROWHEAD PHARMACEUTICALS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 14, 2026 — the most recent Form 4 on file — not from today.
- Form 40001767584-26-000002May 14, 2026
- Form 40000879407-26-000039Apr 24, 2026
- Form 40001830755-26-000007Apr 24, 2026
- Form 40001830755-26-000006Mar 9, 2026
- Form 40001830755-26-000004Jan 8, 2026
- Form 40002081169-26-000002Jan 8, 2026
- Form 40001627183-26-000003Jan 8, 2026
- Form 40001627183-26-000001Jan 5, 2026
- Form 40001830755-26-000002Jan 5, 2026
- Form 40001423029-26-000001Jan 5, 2026
- Form 40001423029-25-000009Dec 30, 2025
- Form 40001506045-25-000007Dec 30, 2025
- Form 40001553338-25-000005Dec 23, 2025
- Form 40001826263-25-000006Dec 23, 2025
- Form 40001423029-25-000007Dec 23, 2025
Fundamentals
XBRL · ARROWHEAD PHARMACEUTICALS, INC.Annual figures sourced directly from ARROWHEAD PHARMACEUTICALS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for ARROWHEAD PHARMACEUTICALS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- 8-KMaterial eventMar 20, 2026
- 10-QQuarterly reportFeb 5, 2026
- 8-KMaterial eventFeb 5, 2026
- DEF 14AProxy statementJan 27, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventJan 9, 2026
- 8-KMaterial eventJan 6, 2026
- 10-KAnnual reportNov 25, 2025
- 8-KMaterial eventNov 25, 2025
- 8-KMaterial eventNov 18, 2025
- 10-K/AAnnual report (amended)Oct 10, 2025
- 8-KMaterial eventSep 12, 2025
- 8-KMaterial eventSep 11, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q2 2026 | open | $77 | $74 | -4% |
| Millennium Management | Q2 2026 | open | $0.00 | — | +0% |
| Point72 Asset Management | Q2 2026 | open | $0.00 | — | +0% |
| Renaissance Technologies | Q2 2026 | open | $80 | $74 | -7% |
| Bridgewater Associates | Q1 2026 | open | $64 | $71 | +12% |
| D.E. Shaw | Q4 2025 | open | $41 | $74 | +79% |
| AQR Capital Management | Q2 2025 | open | $15 | $74 | +382% |
| Renaissance Technologies | Q4 2024 | Q1 2025 | $22 | $19 | -12% |
| Citadel Advisors | Q3 2024 | open | $23 | $74 | +226% |
| Two Sigma Investments | Q3 2024 | Q4 2025 | $23 | $41 | +82% |
| Millennium Management | Q3 2024 | Q2 2026 | $23 | $77 | +238% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.